Aptar Pharma has entered an agreement for Bryn Pharma to use Aptar’s Bidose (BDS) nasal device to deliver Bryn’s epinephrine nasal spray (BRYN-NDS1C).
Crystal Lake, Ill.-based Aptar’s Bidose tech enables two-shot nasal drug delivery and will replace the need to carry two epinephrine auto-injectors, according to the companies. Last March, Aptar won FDA approval to use Bidose for a breakthrough depression therapy.
Bryn Pharma (Raleigh, N.C.) recently completed dosing in the pivotal clinical trial of BRYN-NDS1C using the Aptar device. Up to 30% of patients who develop anaphylaxis will require a second dose of epinephrine to control symptoms, according to Bryn. Current practice parameters recommend that physicians prescribe two epinephrine auto-injectors to be carried by their patients at all times.
“Studies have shown that the majority of people at risk for anaphylaxis do not carry two epinephrine auto-injectors with them at all times, putting them at greater risk of severe complications during an allergic reaction,” said Bryn Pharma CEO David Dworaczyk in a news release. “We are excited to partner with Aptar Pharma to develop a product that can provide patients with a life-saving treatment that fits in a pocket, is easy to use and complies with practice parameters.”
